title: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
abstract: OBJECTIVE
  Efficacy of antifungal prophylaxis has not yet been convincingly proven in numerous trials of various antifungals. New evidence and the anti-Aspergillus efficacy of itraconazole prompted a new look at the data for the prevention of invasive fungal infections.
  
  
  METHODS
  Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients with hematologic malignancies were identified from electronic databases and hand searching.
  
  
  RESULTS
  Thirteen randomized trials included 3,597 patients who were assessable for invasive fungal infections. Itraconazole reduced the incidence of invasive fungal infection (mean relative risk reduction, 40% +/- 13%; P =.002), the incidence of invasive yeast infections (mean, 53% +/- 19%; P =.004) and the mortality from invasive fungal infections (mean, 35% +/- 17%; P =.04) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (mean, 48% +/- 21%; P =.02) and not itraconazole capsules (mean, 75% +/- 73% increase; P =.3). The overall mortality was not changed. Adverse effects were rare, hypokalemia was noted in three studies, and a higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole.
  
  
  CONCLUSIONS
  Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and-shown for the first time for antifungal prophylaxis-reduces mortality from these infections and the rate of invasive Aspergillus infections in neutropenic patients with hematologic malignancies. Adequate doses of the oral cyclodextrine solution (at least 400 mg/d) or i.v. formulations (200 mg/d) of itraconazole are necessary for these effects.
authors.affiliation: Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany. glasmacher@uni-bonn.de
authors.forename: Axel
authors.initials: A
authors.lastname: Glasmacher
authors.forename: Archibald
authors.initials: A
authors.lastname: Prentice
authors.forename: Marcus
authors.initials: M
authors.lastname: Gorschlüter
authors.forename: Steffen
authors.initials: S
authors.lastname: Engelhart
authors.forename: Corinna
authors.initials: C
authors.lastname: Hahn
authors.forename: Benjamin
authors.initials: B
authors.lastname: Djulbegovic
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D009181:Mycoses / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole